NURS 6512 Exam 1 V1 | NURS 6512 Advanced Pharmacology | Actual
Q&A with Rationale (NURS 6512 Exam 1) | Walden
1. A 64-year-old male, Mr. Henderson, is prescribed warfarin for atrial fibrillation. His latest
lab results indicate a significantly elevated INR, although he denies missing doses or changing
his diet. Upon review, he recently started taking high-dose aspirin for joint pain. Which
pharmacokinetic principle best explains this interaction?
A. Enzyme induction of CYP2C9 by aspirin.
B. Inhibition of gastric absorption of warfarin.
C. Reduced renal clearance of warfarin due to aspirin.
D. Competition for plasma protein binding sites.
Answer: D
Rationale: Both warfarin and aspirin are highly protein-bound drugs that compete for
binding sites on albumin. When aspirin is added, it can displace warfarin, increasing the
amount of free, active warfarin in the bloodstream. This leads to an intensified
anticoagulant effect and a higher risk of bleeding, as reflected by the elevated INR.
2. A 28-year-old female patient, Sarah, is diagnosed with a severe infection and is started on a
medication with a narrow therapeutic index. The Nurse Practitioner (NP) orders therapeutic
drug monitoring (TDM). What is the primary clinical rationale for performing TDM in this
scenario?
A. To ensure the drug reaches steady-state within the first two hours.
B. To verify the patient’s genetic predisposition to drug metabolism.
C. To determine if the drug is undergoing significant first-pass metabolism.
D. To maintain the drug concentration within a range that is both effective and non-toxic.
Answer: D
Rationale: Drugs with a narrow therapeutic index have a small margin between the
minimum effective concentration and the minimum toxic concentration. TDM is essential to
monitor these levels and adjust dosages to prevent adverse reactions while ensuring
therapeutic efficacy. This process is a hallmark of safe, evidence-based medication
management in advanced practice.
3. Mrs. Rodriguez, a 72-year-old female with chronic kidney disease (Stage 3), requires a new
prescription for an antibiotic primarily excreted by the kidneys. How should the NP adjust the
dosing regimen based on her physiological status?
A. Increase the dose to ensure adequate tissue penetration.
,B. Decrease the dosing interval to maintain serum levels.
C. Change the administration route to intramuscular for faster absorption.
D. Decrease the dose or lengthen the dosing interval.
Answer: D
Rationale: In patients with impaired renal function, the clearance of drugs excreted by the
kidneys is reduced, leading to potential accumulation and toxicity. The NP must calculate
the glomerular filtration rate (GFR) or creatinine clearance to determine appropriate
adjustments. This typically involves reducing the dose or increasing the time between
doses to account for the slower elimination rate.
4. An NP is treating a 3-week-old neonate for a suspected bacterial infection. Which factor
regarding neonatal pharmacokinetics must the NP consider when calculating the dose?
A. Neonates have higher levels of plasma proteins compared to adults.
B. The blood-brain barrier is fully developed, preventing CNS side effects.
C. Gastric emptying is faster than in adults, leading to rapid drug absorption.
D. Renal excretion is significantly reduced due to immature glomerular filtration.
Answer: D
Rationale: Neonate physiology is characterized by immature organ systems, specifically
the liver and kidneys. The glomerular filtration rate is only about 30% to 50% of adult
levels, which significantly slows the excretion of many drugs. This necessitates careful
weight-based dosing and extended dosing intervals to prevent toxic accumulation.
5. A 45-year-old patient is prescribed a prodrug that requires activation by the CYP2D6
enzyme. Genetic testing reveals the patient is a ‘poor metabolizer’ at this locus. What is the
most likely clinical outcome for this patient?
A. The patient will experience rapid toxicity due to high active drug levels.
B. The patient will experience an immediate hypersensitivity reaction.
C. The drug will remain in the system longer, requiring a dose reduction.
D. The drug will have little to no therapeutic effect.
Answer: D
Rationale: A prodrug is an inactive compound that must be metabolized into its active
form by specific enzymes. If a patient is a poor metabolizer of the required enzyme
(CYP2D6), they cannot convert the prodrug efficiently. Consequently, the patient will not
achieve therapeutic levels of the active drug, rendering the treatment ineffective.
, 6. Mr. Thompson, a 55-year-old patient with chronic pain, has been taking an opioid agonist
for three months. He reports that the medication is no longer providing the same level of
pain relief as it did initially. This phenomenon is best described as:
A. Drug-drug interaction.
B. Tolerance.
C. Tachyphylaxis.
D. Physical dependence.
Answer: B
Rationale: Tolerance occurs when a subject’s response to a specific drug concentration
progressively decreases over time with repeated use. In the context of opioids, this often
involves the down-regulation of receptors or changes in signal transduction. To achieve the
same therapeutic effect, a higher dose of the medication is eventually required.
7. Which of the following describes a ‘Type B’ adverse drug reaction (ADR) in a clinical
setting?
A. An anaphylactic reaction to a first-time dose of penicillin.
B. Bradycardia resulting from a standard dose of a beta-blocker.
C. Hypoglycemia caused by an overdose of insulin.
D. Dry mouth associated with the use of an anticholinergic drug.
Answer: A
Rationale: Type B ADRs are idiosyncratic, unpredictable, and not related to the known
pharmacological action of the drug. They are often immune-mediated, such as
hypersensitivity or anaphylaxis, and can occur even at low doses. In contrast, Type A
reactions are predictable and dose-dependent exaggerations of the drug’s intended effect.
8. An NP is reviewing the pharmacokinetics of a new lipophilic medication. In an obese
patient, how would the volume of distribution (Vd) for this drug likely be affected?
A. The Vd will be decreased due to reduced blood flow to adipose tissue.
B. The Vd will be increased due to higher plasma protein levels in obesity.
C. The Vd will remain unchanged as adipose tissue does not affect drug distribution.
D. The Vd will be increased because the drug will distribute into the excess adipose tissue.
Answer: D
Rationale: Lipophilic (fat-soluble) drugs have a high affinity for adipose tissue. In obese
patients, the increased percentage of body fat provides a larger reservoir for these drugs to
Q&A with Rationale (NURS 6512 Exam 1) | Walden
1. A 64-year-old male, Mr. Henderson, is prescribed warfarin for atrial fibrillation. His latest
lab results indicate a significantly elevated INR, although he denies missing doses or changing
his diet. Upon review, he recently started taking high-dose aspirin for joint pain. Which
pharmacokinetic principle best explains this interaction?
A. Enzyme induction of CYP2C9 by aspirin.
B. Inhibition of gastric absorption of warfarin.
C. Reduced renal clearance of warfarin due to aspirin.
D. Competition for plasma protein binding sites.
Answer: D
Rationale: Both warfarin and aspirin are highly protein-bound drugs that compete for
binding sites on albumin. When aspirin is added, it can displace warfarin, increasing the
amount of free, active warfarin in the bloodstream. This leads to an intensified
anticoagulant effect and a higher risk of bleeding, as reflected by the elevated INR.
2. A 28-year-old female patient, Sarah, is diagnosed with a severe infection and is started on a
medication with a narrow therapeutic index. The Nurse Practitioner (NP) orders therapeutic
drug monitoring (TDM). What is the primary clinical rationale for performing TDM in this
scenario?
A. To ensure the drug reaches steady-state within the first two hours.
B. To verify the patient’s genetic predisposition to drug metabolism.
C. To determine if the drug is undergoing significant first-pass metabolism.
D. To maintain the drug concentration within a range that is both effective and non-toxic.
Answer: D
Rationale: Drugs with a narrow therapeutic index have a small margin between the
minimum effective concentration and the minimum toxic concentration. TDM is essential to
monitor these levels and adjust dosages to prevent adverse reactions while ensuring
therapeutic efficacy. This process is a hallmark of safe, evidence-based medication
management in advanced practice.
3. Mrs. Rodriguez, a 72-year-old female with chronic kidney disease (Stage 3), requires a new
prescription for an antibiotic primarily excreted by the kidneys. How should the NP adjust the
dosing regimen based on her physiological status?
A. Increase the dose to ensure adequate tissue penetration.
,B. Decrease the dosing interval to maintain serum levels.
C. Change the administration route to intramuscular for faster absorption.
D. Decrease the dose or lengthen the dosing interval.
Answer: D
Rationale: In patients with impaired renal function, the clearance of drugs excreted by the
kidneys is reduced, leading to potential accumulation and toxicity. The NP must calculate
the glomerular filtration rate (GFR) or creatinine clearance to determine appropriate
adjustments. This typically involves reducing the dose or increasing the time between
doses to account for the slower elimination rate.
4. An NP is treating a 3-week-old neonate for a suspected bacterial infection. Which factor
regarding neonatal pharmacokinetics must the NP consider when calculating the dose?
A. Neonates have higher levels of plasma proteins compared to adults.
B. The blood-brain barrier is fully developed, preventing CNS side effects.
C. Gastric emptying is faster than in adults, leading to rapid drug absorption.
D. Renal excretion is significantly reduced due to immature glomerular filtration.
Answer: D
Rationale: Neonate physiology is characterized by immature organ systems, specifically
the liver and kidneys. The glomerular filtration rate is only about 30% to 50% of adult
levels, which significantly slows the excretion of many drugs. This necessitates careful
weight-based dosing and extended dosing intervals to prevent toxic accumulation.
5. A 45-year-old patient is prescribed a prodrug that requires activation by the CYP2D6
enzyme. Genetic testing reveals the patient is a ‘poor metabolizer’ at this locus. What is the
most likely clinical outcome for this patient?
A. The patient will experience rapid toxicity due to high active drug levels.
B. The patient will experience an immediate hypersensitivity reaction.
C. The drug will remain in the system longer, requiring a dose reduction.
D. The drug will have little to no therapeutic effect.
Answer: D
Rationale: A prodrug is an inactive compound that must be metabolized into its active
form by specific enzymes. If a patient is a poor metabolizer of the required enzyme
(CYP2D6), they cannot convert the prodrug efficiently. Consequently, the patient will not
achieve therapeutic levels of the active drug, rendering the treatment ineffective.
, 6. Mr. Thompson, a 55-year-old patient with chronic pain, has been taking an opioid agonist
for three months. He reports that the medication is no longer providing the same level of
pain relief as it did initially. This phenomenon is best described as:
A. Drug-drug interaction.
B. Tolerance.
C. Tachyphylaxis.
D. Physical dependence.
Answer: B
Rationale: Tolerance occurs when a subject’s response to a specific drug concentration
progressively decreases over time with repeated use. In the context of opioids, this often
involves the down-regulation of receptors or changes in signal transduction. To achieve the
same therapeutic effect, a higher dose of the medication is eventually required.
7. Which of the following describes a ‘Type B’ adverse drug reaction (ADR) in a clinical
setting?
A. An anaphylactic reaction to a first-time dose of penicillin.
B. Bradycardia resulting from a standard dose of a beta-blocker.
C. Hypoglycemia caused by an overdose of insulin.
D. Dry mouth associated with the use of an anticholinergic drug.
Answer: A
Rationale: Type B ADRs are idiosyncratic, unpredictable, and not related to the known
pharmacological action of the drug. They are often immune-mediated, such as
hypersensitivity or anaphylaxis, and can occur even at low doses. In contrast, Type A
reactions are predictable and dose-dependent exaggerations of the drug’s intended effect.
8. An NP is reviewing the pharmacokinetics of a new lipophilic medication. In an obese
patient, how would the volume of distribution (Vd) for this drug likely be affected?
A. The Vd will be decreased due to reduced blood flow to adipose tissue.
B. The Vd will be increased due to higher plasma protein levels in obesity.
C. The Vd will remain unchanged as adipose tissue does not affect drug distribution.
D. The Vd will be increased because the drug will distribute into the excess adipose tissue.
Answer: D
Rationale: Lipophilic (fat-soluble) drugs have a high affinity for adipose tissue. In obese
patients, the increased percentage of body fat provides a larger reservoir for these drugs to
